Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
cannabis indica/antifungal
Kiungo kimehifadhiwa kwenye clipboard
Ukurasa 1 kutoka 66 matokeo
Cannabis-based therapeutic product for treatment of chronic pain
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention is in the field of cannabis active compound formulation for medicinal application. Specifically, the use of formulations containing cannabis-derived compounds as medical treatments for chronic pain.
Discussion of the State of
Therapeutic use of mono and bicarboxylic acid amides active at the peripheral cannabinoid receptor
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The present invention relates to a therapeutic method for the treatment of diseases connected with the modulation of the cannabinoid peripheral receptor, comprising administering amidic derivatives of mono and bicarboxylic acids with substituted aminoalcohols or
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD
The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2.
BACKGROUND
Osteoporosis is a major metabolic bone disease that affects 44 million Americans
Cannabinoid receptor 2 (CB2) inverse agonists and therapeutic potential for multiple myeloma and osteoporosis bone diseases
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD
The present invention relates to compounds by the regulation of cannabinoid receptors. More specifically, the compounds are inverse antagonists of cannabinoid receptor subtype-2, otherwise known as CB2.
BACKGROUND
Osteoporosis is a major metabolic bone disease that affects 44 million Americans
Compositions including quinonoid derivatives of cannabinoids for therapeutic use
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The present invention relates to the field of cannabinoids. More specifically, the present invention describes the medical use of some quinonoid derivatives of cannabinoids, as well as some such novel compounds.
BACKGROUND OF THE INVENTION
All publications mentioned throughout
Therapeutic agents containing cannabis flavonoid derivative for ocular disorders
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to flavonoid derivatives and, more particularly, to cannabis flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating ocular
Therapeutic agents containing cannabis flavonoid derivative for ocular disorders
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to flavonoid derivatives and, more particularly, to cannabis flavonoid derivatives or the pharmaceutically acceptable salt thereof that may be used in a pharmaceutical composition for preventing and treating ocular
Cannabis based therapeutic and method of use
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The present invention relates to therapeutics, and more especially cannabis based therapeutics for use in treating those known to have or be at increased risk of endometriosis and other ailments.
BACKGROUND OF THE INVENTION
Endometriosis is a common gynecological disorder.
Enhanced smokable therapeutic cannabis product and method for making same
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Field of the Invention
The present invention is in the field of therapeutic uses of the cannabis plant, and more specifically the field of therapeutic smokable products derived from cannabis.
Discussion of the State of the Art
Recently, multiple states have passed
Keto cannabinoids with therapeutic indications
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
This invention relates generally to cannabinoid compounds. One embodiment of the present invention more particularly relates to cannabinoid compounds exhibiting fluorescence properties, particularly in the ultraviolet-visible wavelength ranges.
BACKGROUND OF THE INVENTION
The
Tetrahydroquinoline cannabinoid receptor modulators
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,
Pyrazine modulators of cannabinoid receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite,
Triazolopyrimidine cannabinoid receptor 1 antagonists
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,
Triazolopyridine cannabinoid receptor 1 antagonists
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite, immunosuppression,
Azabicyclic heterocycles as cannabinoid receptor modulators
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND OF THE INVENTION
Delta-9-tetrahydrocannabinol or Delta-9 THC, the principle active component of Cannabis sativa (marijuana), is a member of a large family of lipophilic compounds (i.e., cannabinoids) that mediate physiological and psychotropic effects including regulation of appetite,
Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi
- Inafanya kazi katika lugha 55
- Uponyaji wa mitishamba unaungwa mkono na sayansi
- Kutambua mimea kwa picha
- Ramani ya GPS inayoshirikiana
- Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
- Tafuta mimea ya dawa na athari zao
- Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu
Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa
